Aquestive Therapeutics (AQST) reported $14.45 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 65.7%. EPS of -$0.07 for the same period compares to -$0.24 a year ago.
The reported revenue compares to the Zacks Consensus Estimate of $10.84 million, representing a surprise of +33.22%. The company delivered an EPS surprise of +50%, with the consensus EPS estimate being -$0.14.
While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.
As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.
Here is how Aquestive Therapeutics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenues- Manufacture and supply revenue: $8.79 million compared to the $8.24 million average estimate based on two analysts. The reported number represents a change of +22.2% year over year. Revenues- Co-development and research fees: $0.26 million versus $0.4 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -38.3% change. Revenues- License and royalty revenue: $5.4 million versus $1 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a +582.9% change.View all Key Company Metrics for Aquestive Therapeutics here>>>
Shares of Aquestive Therapeutics have returned +0.2% over the past month versus the Zacks S&P 500 composite's +8.6% change. The stock currently has a Zacks Rank #4 (Sell), indicating that it could underperform the broader market in the near term.Zacks' Research Chief Names "Stock Most Likely to Double"
Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest.
This top pick is a little-known satellite-based communications firm. Space is projected to become a trillion dollar industry, and this company's customer base is growing fast. Analysts have forecasted a major revenue breakout in 2025. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Hims & Hers Health, which shot up +209%.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Aquestive Therapeutics, Inc. (AQST): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).